<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34881804</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>09</Day></DateCompleted><DateRevised><Year>2022</Year><Month>06</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1699-5848</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Histology and histopathology</Title><ISOAbbreviation>Histol Histopathol</ISOAbbreviation></Journal><ArticleTitle>Adenosine deaminase, not immune to a mechanistic rethink in central nervous system disorders?</ArticleTitle><Pagination><StartPage>189</StartPage><EndPage>212</EndPage><MedlinePgn>189-212</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.14670/HH-18-404</ELocationID><Abstract><AbstractText>Adenosine deaminase (ADA) is a purine metabolism enzyme that catalyses the breakdown of adenosine and deoxyadenosine. The enzyme is important in several cellular processes, including the innate immune response and cellular differentiation, and it is also an important enzyme for the maintenance of brain homeostasis, in part due to its regulation of adenosine. Aberrant regulation of ADA enzyme activity has been linked to several neurodegenerative diseases and diseases that can result in neurological impairment. However, the mechanisms behind altered ADA regulation and how this leads to the development of neurological dysfunction are poorly characterised. This review summarises the current research on ADA and its role and regulation in disease pathology, with a focus on the central nervous system (CNS) and the neurodegenerative disease, amyotrophic lateral sclerosis (ALS).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK. bpchall1@sheffield.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>George</LastName><ForeName>Jonathan G</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allen</LastName><ForeName>Scott P</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>SBF005\1064</GrantID><Agency>Sheffield Neuroscience Institute and Academy of Medical Sciences</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Histol Histopathol</MedlineTA><NlmUniqueID>8609357</NlmUniqueID><ISSNLinking>0213-3911</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.5.4.4</RegistryNumber><NameOfSubstance UI="D000243">Adenosine Deaminase</NameOfSubstance></Chemical><Chemical><RegistryNumber>K72T3FS567</RegistryNumber><NameOfSubstance UI="D000241">Adenosine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000241" MajorTopicYN="N">Adenosine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000243" MajorTopicYN="N">Adenosine Deaminase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>9</Day><Hour>8</Hour><Minute>41</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34881804</ArticleId><ArticleId IdType="doi">10.14670/HH-18-404</ArticleId><ArticleId IdType="pii">HH-18-404</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abe K., Aoki M., Tsuji S., Itoyama Y., Sobue G., Togo M., Hamada C., Tanaka M., Akimoto M., Nakamura K., Takahashi F., Kondo K. and Yoshino H. (2017). Safety and Efficacy of Edaravone in Well Defined Patients with Amyotrophic Lateral Sclerosis: A Randomised, Double-Blind, Placebo-Controlled Trial. Lancet. Neurol. 16, 505-512.</Citation><ArticleIdList><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu Shmais G.A., Al-Ayadhi L.Y., Al-Dbass A.M. and El-Ansary A.K. (2012). Mechanism of Nitrogen Metabolism-Related Parameters and Enzyme Activities in the Pathophysiology of Autism. J. Neurodev. Dis. 4, 1-11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3374296</ArticleId><ArticleId IdType="pubmed">22958401</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguirre N., Beal M.F., Matson W.R. and Bogdanov M.B. (2009). Increased Oxidative Damage to DNA in an Animal Model of Amyotrophic Lateral Sclerosis. Free Radic. Res. 39, 383- 388.</Citation><ArticleIdList><ArticleId IdType="pubmed">16028363</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn C., Kang J.H. and Jeung E.B. (2017). Calcium Homeostasis in Diabetes Mellitus. J. Vet. Sci. 18, 261-266</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5639077</ArticleId><ArticleId IdType="pubmed">28927245</ArticleId></ArticleIdList></Reference><Reference><Citation>Aiuti A., Cattaneo F., Galimberti S., Benninghoff U., Cassani B., Callegaro L., Scaramuzza S., Andolfi G., Mirolo M., Brigida I., Tabucchi A., Carlucci F., Eibl M., Aker M., Slavin S., Al- Mousa H., Al Ghonaium A., Ferster A., Duppenthaler A., Notarangelo L., Wintergerst U., Buckley R.H., Bregni M., Marktel S., Valsecchi M.G., Rossi P., Ciceri F., Miniero R., Bordignon C. and Roncarolo M.G. (2009). Gene Therapy for Immunodeficiency Due to Adenosine Deaminase Deficiency. N. Engl. J. Med. 360, 447-458</Citation><ArticleIdList><ArticleId IdType="pubmed">19179314</ArticleId></ArticleIdList></Reference><Reference><Citation>Aizawa H., Sawada J., Hideyama T., Yamashita T., Katayama T., Hasebe N., Kimura T., Yahara O. and Kwak S. (2010). TDP-43 Pathology in Sporadic ALS Occurs in Motor Neurons Lacking the RNA Editing Enzyme ADAR2. Acta Neuropathol. 120, 75-84.</Citation><ArticleIdList><ArticleId IdType="pubmed">20372915</ArticleId></ArticleIdList></Reference><Reference><Citation>Aldrich M-B., Chen W., Blackburn M-R., Martinez-Valdez H., Datta S-K. and Kellems R-E. (2003). Impaired Germinal Center Maturation in Adenosine Deaminase Deficiency. J. Immunol. 171, 5562-5570.</Citation><ArticleIdList><ArticleId IdType="pubmed">14607964</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen S.P., Hall B., Castelli L.M., Francis L., Woof R., Siskos A.P., Kouloura E., Gray E., Thompson A.G., Talbot K., Higginbottom A., Myszczynska M., Allen C.F., Stopford M.J., Hemingway J., Bauer C.S., Webster C.P., De Vos K.J., Turner M.R., Keun H.C., Hautbergue G.M., Ferraiuolo L. and Shaw P.J. (2019). Astrocyte Adenosine Deaminase Loss Increases Motor Neuron Toxicity in Amyotrophic Lateral Sclerosis. Brain. 142, 586- 605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6391613</ArticleId><ArticleId IdType="pubmed">30698736</ArticleId></ArticleIdList></Reference><Reference><Citation>Ames B.N., Cathcart R., Schwiers E. and Hochstein P. (1981). Uric Acid Provides an Antioxidant Defense in Humans against Oxidant- and Radical-Caused Aging and Cancer: A Hypothesis. Proc. Natl. Acad. Sci. USA 78, 6858-6862</Citation><ArticleIdList><ArticleId IdType="pmc">PMC349151</ArticleId><ArticleId IdType="pubmed">6947260</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrade N.S., Ramic M., Esanov R., Liu W., Rybin M.J., Gaidosh G., Abdallah A., Del'Olio S., Huff T.C., Chee N.T., Anatha S., Gendron T.F., Wahlestedt C., Zhang Y., Benatar M., Mueller C. and Zeier Z. (2020). Dipeptide Repeat Proteins Inhibit Homology-Directed DNA Double Strand Break Repair in C9ORF72 ALS/FTD. Mol. Neurodegener. 15, 13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7041170</ArticleId><ArticleId IdType="pubmed">32093728</ArticleId></ArticleIdList></Reference><Reference><Citation>Ansoleaga B., Jov&#xe9; M., Schl&#xfc;ter A., Garcia-Esparcia P., Moreno J., Pujol A., Pamplona R., Portero-Ot&#xed;n M. and Ferrer I. (2015). Deregulation of Purine Metabolism in Alzheimer&#x2019;s Disease. Neurobiol. Aging. 36, 68-80.</Citation><ArticleIdList><ArticleId IdType="pubmed">25311278</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonioli L., Colucci R., La Motta C., Tuccori M., Awwad O., Da Settimo F., Blandizzi C. and Fornai M. (2012). Adenosine Deaminase in the Modulation of Immune System and Its Potential as a Novel Target for Treatment of Inflammatory Disorders. Curr. Drug Targets. 13, 842-862.</Citation><ArticleIdList><ArticleId IdType="pubmed">22250650</ArticleId></ArticleIdList></Reference><Reference><Citation>Appleby-Mallinder C., Schaber E., Kirby J., Shaw P.J., Cooper-Knock J., Heath P.R. and Highley J.R. (2021). TDP43 Proteinopathy Is Associated with Aberrant DNA Methylation in Human Amyotrophic Lateral Sclerosis. Neuropathol. Appl. Neurobiol. 47, 61-72.</Citation><ArticleIdList><ArticleId IdType="pubmed">32365404</ArticleId></ArticleIdList></Reference><Reference><Citation>Arredondo-Vega F.X., Santisteban I., Kelly S., Schlossman C.M., Umetsu D.T. and Hershfield M.S. (1994). Correct Splicing despite Mutation of the Invariant First Nucleotide of a 5&#x2019; Splice Site: A Possible Basis for Disparate Clinical Phenotypes in Siblings with Adenosine Deaminase Deficiency. Am. J. Hum. Genet. 54, 820-830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1918276</ArticleId><ArticleId IdType="pubmed">8178821</ArticleId></ArticleIdList></Reference><Reference><Citation>Arredondo-Vega F.X., Santisteban I., Daniels S., Toutain S. and Hershfield M.S. (1998). Adenosine Deaminase Deficiency: Genotype-Phenotype Correlations Based on Expressed Activity of 29 Mutant Alleles. Am. J. Hum. Genet. 63, 1049-1059.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1377486</ArticleId><ArticleId IdType="pubmed">9758612</ArticleId></ArticleIdList></Reference><Reference><Citation>Arredondo-Vega F.X., Santisteban I., Richard E., Bali P., Koleilat M., Loubser M., Al- Ghonaium A., Al-Helali M. and Hershfield M.S. (2002). Adenosine Deaminase Deficiency with Mosaicism for a &#x2018;Second-Site Suppressor&#x2019; of a Splicing Mutation: Decline in Revertant T Lymphocytes during Enzyme Replacement Therapy. Blood. 99, 1005-1013.</Citation><ArticleIdList><ArticleId IdType="pubmed">11807006</ArticleId></ArticleIdList></Reference><Reference><Citation>Aryanpour R., Zibara K., Pasbakhsh P., Jame&#x2019;ei S.B., Namjoo Z., Ghanbari A., Mahmoudi R., Amani S. and Kashani I.R. (2021). 17&#x3b2;-Estradiol Reduces Demyelination in Cuprizone- Fed Mice by Promoting M2 Microglia Polarity and Regulating NLRP3 Inflammasome. Neuroscience. 463, 116-127</Citation><ArticleIdList><ArticleId IdType="pubmed">33794337</ArticleId></ArticleIdList></Reference><Reference><Citation>Atasoy U., Norby-Slycord C.J. and Markert M.L. (1993). A Missense Mutation in Exon 4 of the Human Adenosine Deaminase Gene Causes Severe Combined Immunodeficiency. Hum. Mol. Genet. 2, 1307-1308.</Citation><ArticleIdList><ArticleId IdType="pubmed">7691348</ArticleId></ArticleIdList></Reference><Reference><Citation>Balendra R. and Isaacs A.M. (2018). C9orf72-Mediated ALS and FTD: Multiple Pathways to Disease. Nat. Rev. Neurol. 14, 544-558</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6417666</ArticleId><ArticleId IdType="pubmed">30120348</ArticleId></ArticleIdList></Reference><Reference><Citation>Balestri F., Giannecchini M., Sgarrella F., Carta M.C., Tozzi M.G. and Camici M. (2007). Purine and Pyrimidine Nucleosides Preserve Human Astrocytoma Cell Adenylate Energy Charge under Ischemic Conditions. Neurochem. Int. 50, 517-523.</Citation><ArticleIdList><ArticleId IdType="pubmed">17126452</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbosa L.F., Cerqueira F.M., Macedo A.F.A., Garcia C.C.M., Angeli J.P.F., Schumacher R.I., Sogayar M.C., Augusto O., Carr&#xec; M.T., Di Mascio P. and Medeirosa M.H.G. (2010). Increased SOD1 Association with Chromatin, DNA Damage, P53 Activation and Apoptosis in a Cellular Model of SOD1-Linked ALS. Biochim. Biophys. Acta. 1802, 462- 471.</Citation><ArticleIdList><ArticleId IdType="pubmed">20097285</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR., Zhao W., Wang J., Zhang X., Wen S., Neal D., Thonhoff JR., Alsuliman AS., Shpall EJ., Rezvani K. and Appel SH. (2017). ALS patients&#x2019; regulatory T lymphocytes are dysfunctional and correlate with disease progression rate and severity. JCI Insight. 2, 89530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5333967</ArticleId><ArticleId IdType="pubmed">28289705</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe9;land L-C., Markovinovic A., Jakovac H., De Marchi F., Bilic E., Mazzini L., Kriz J. and Munitic I. (2020). Immunity in amyotrophic lateral sclerosis: Blurred lines between excessive inflammation and inefficient immune responses. Brain Commun. 2, 124</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7585698</ArticleId><ArticleId IdType="pubmed">33134918</ArticleId></ArticleIdList></Reference><Reference><Citation>Belot A., Wassmer E., Twilt M., Lega J-C., Zeef L.A.H., Oojageer A., Kasher P.R., Mathieu A.L., Malcus C., Demaret J., Fabien N., Collardeau-Frachon S., Mechtouff L., Derex L., Walzer T., Rice G.I., Durieu I. and Crow Y.J. (2014). Mutations in CECR1 associated with a neutrophil signature in peripheral blood. Pediatr. Rheumatol. Online J. 12, 44</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4181355</ArticleId><ArticleId IdType="pubmed">25278816</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G., Lacomblez L. and Meininger V. (1994). A controlled trial of riluzole in amyotrophic lateral sclerosis. N. Engl. J. Med. 330, 585-591.</Citation><ArticleIdList><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Benveniste P., Zhu W. and Cohen A. (1995). Interference with thymocyte differentiation by an inhibitor of S-adenosylhomocysteine hydrolase. J. Immunol. 155, 536-544.</Citation><ArticleIdList><ArticleId IdType="pubmed">7608534</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasco H., Garcon G., Patin F., Veyrat-Durebex C., Boyer J., Devos D., Vourc&#x2019;h P., Andres C.R. and Corcia P. (2017). Panel of oxidative stress and inflammatory biomarkers in ALS: A pilot study. Can. J. Neurol. Sci. 44, 90-95.</Citation><ArticleIdList><ArticleId IdType="pubmed">27774920</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogdanov M., Brown R.H., Matson W., Smart R., Hayden D., O&#x2019;Donnell H., Beal M.F. and Cudkowicz M. (2000). Increased oxidative damage to DNA in ALS patients. Free Rad. Biol. Med. 29, 652-658.</Citation><ArticleIdList><ArticleId IdType="pubmed">11033417</ArticleId></ArticleIdList></Reference><Reference><Citation>Bottini N., De Luca D., Saccucci P., Fiumara A., Elia M., Porfirio M.C., Lucarelli P. and Curatolo P. (2001). Autism: Evidence of association with adenosine deaminase genetic polymorphism. Neurogenetics 3, 111-113.</Citation><ArticleIdList><ArticleId IdType="pubmed">11354825</ArticleId></ArticleIdList></Reference><Reference><Citation>Boulton T.G., Yancopoulos G.D., Gregory J.S., Slaughter C., Moomaw C., Hsu J. and Cobb M.H. (1990). An insulin-stimulated protein kinase similar to yeast kinases involved in cell cycle control. Science 249, 64-67.</Citation><ArticleIdList><ArticleId IdType="pubmed">2164259</ArticleId></ArticleIdList></Reference><Reference><Citation>Brasil A.A., Magalh&#xe3;es R.S.S., De Carvalho M.C.C., Paiva I., Gerhardt E., Pereira M.D., Outeiro T.F. and Eleutherio E.C.A. (2018). Implications of FALS mutations on SOD1 function and oligomerization in cell models. Mol. Neurobiol. 55, 5269-5281.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5948255</ArticleId><ArticleId IdType="pubmed">28884318</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulut E., Erden A., Karadag O., Oguz K.K. and Ozen S. (2019). Deficiency of adenosine deaminase 2; Special focus on central nervous system imaging. J. Neuroradiol. 46, 193-198.</Citation><ArticleIdList><ArticleId IdType="pubmed">29913178</ArticleId></ArticleIdList></Reference><Reference><Citation>Camici M., Allegrini S. and Tozzi M.G. (2018). Interplay between adenylate metabolizing enzymes and AMP-activated protein kinase. The FEBS J. 285, 3337-3352.</Citation><ArticleIdList><ArticleId IdType="pubmed">29775996</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancino G.I., Miller F.D. and Kaplan D.R. (2013). P73 haploinsufficiency causes tau hyperphosphorylation and tau kinase dysregulation in mouse models of aging and Alzheimer&#x2019;s disease. Neurobiol. Aging 34, 387-399.</Citation><ArticleIdList><ArticleId IdType="pubmed">22592019</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantoni G.L. (1953). S-adenosylmethionine; A new intermediate formed enzymatically from L-methionine and adenosinetriphosphate. J. Biol. Chem. 204, 403-416.</Citation><ArticleIdList><ArticleId IdType="pubmed">13084611</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmona-Rivera C., Khaznadar S.S., Shwin K.W., Irizarry-Caro J.A., O&#x2019;Neil L.J., Liu Y., Jacobson K.A., Ombrello A.K., Stone D.L., Tsai W.L., Kastner D., Aksentijevich I., Kaplan M.J. and Grayson P.C. (2019). Deficiency of adenosine deaminase 2 triggers adenosinemediated NETosis and TNF production in patients with DADA2. Blood 134, 395-406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6659253</ArticleId><ArticleId IdType="pubmed">31015188</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson D.A., Kaye J., Matsumoto S., Seegmiller J.E. and Thompson L. (1979). Biochemical basis for the enhanced toxicity of deoxyribonucleosides toward malignant human T cell lines. Proc. Natl. Acad. Sci. USA 76, 2430-2433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC383615</ArticleId><ArticleId IdType="pubmed">313056</ArticleId></ArticleIdList></Reference><Reference><Citation>Castillo C.A., Albasanz J.L., Le&#xf3;n D., Jord&#xe1;n J., Pall&#xe0;s M., Camins A. and Mart&#xed;n M. (2009). Age-related expression of adenosine receptors in brain from the senescence-accelerated mouse. Exp. Gerontol. 44, 453-461.</Citation><ArticleIdList><ArticleId IdType="pubmed">19410642</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X., Burdett T.C., Desjardins C.A., Logan R., Cipriani S., Xu Y. and Schwarzschild M.A. (2013). Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration. Proc. Natl. Acad. Sci. USA 110, 300-305.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3538212</ArticleId><ArticleId IdType="pubmed">23248282</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X., Wu G. and Schwarzschild M.A. (2012). Urate in Parkinson&#x2019;s disease: More than a biomarker? Curr. Neurol. Neurosci. Rep. 12, 367-375.</Citation><ArticleIdList><ArticleId IdType="pubmed">22580741</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiba S., Matsumoto H., Saitoh M., Kasahara M., Matsuya M. and Kashiwagi M. (1995). A correlation study between serum adenosine deaminase activities and peripheral lymphocyte subsets in Parkinson&#x2019;s disease. J. Neurol. Sci. 132, 170-173.</Citation><ArticleIdList><ArticleId IdType="pubmed">8543943</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi S.Y., Lopez-Gonzalez R., Krishnan G., Phillips HL., Li A.N., Seeley W.W., Yao W.D., Almeida S. and Gao F.B. (2019). C9ORF72- ALS/FTD-associated poly(GR) binds Atp5a1 and compromises mitochondrial function in vivo. Nat. Neurosci. 22, 851-862.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6800116</ArticleId><ArticleId IdType="pubmed">31086314</ArticleId></ArticleIdList></Reference><Reference><Citation>Chottiner E.G., Cloft H.J., Tartaglia A.P. and Mitchell B.S. (1987). Elevated adenosine deaminase activity and hereditary hemolytic anemia. Evidence for abnormal translational control of protein synthesis. J. Clin. Invest. 79, 1001-1005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC424261</ArticleId><ArticleId IdType="pubmed">3029177</ArticleId></ArticleIdList></Reference><Reference><Citation>Chunn J.L., Molina J.G., Mi T., Xia Y., Kellems R.E. and Blackburn M.R. (2005). Adenosine-dependent pulmonary fibrosis in adenosine deaminase-deficient mice. J. Immunol. 175, 1937-1946.</Citation><ArticleIdList><ArticleId IdType="pubmed">16034138</ArticleId></ArticleIdList></Reference><Reference><Citation>Cicalese M.P., Ferrua F., Castagnaro L., Pajno R., Barzaghi F., Giannelli S., Dionisio F., Brigida I., Bonopane M., Casiraghi M., Tabucchi A., Carlucci F., Grunebaum E., Adeli M., Bredius R.G., Puck J.M., Stepensky P., Tezcan I., Rolfe K., De Boever E., Reinhardt R.R., Appleby J., Ciceri F., Roncarolo M. and Aiuti A. (2016). Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency. Blood 128, 45-54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5325048</ArticleId><ArticleId IdType="pubmed">27129325</ArticleId></ArticleIdList></Reference><Reference><Citation>Cie&#x15b;lak M., Roszek K. and Wujak M. (2018). Purinergic implication in amyotrophic lateral sclerosis-from pathological mechanisms to therapeutic perspectives. Purinergic Signal 15, 1-15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6439052</ArticleId><ArticleId IdType="pubmed">30430356</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen A., Hirschhorn R., Horowitz S.D., Rubinstein A., Polmar S.H., Hong R. and Martin D.W. (1978). Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency. Proc. Natl. Acad. Sci. USA 75, 472-476.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC411272</ArticleId><ArticleId IdType="pubmed">272665</ArticleId></ArticleIdList></Reference><Reference><Citation>Copped&#xe8; F., Stoccoro A., Mosca L., Gallo R., Tarlarini C., Lunetta C., Marocchi A., Migliore L. and Penco S. (2017). Increase in DNA methylation in patients with amyotrophic lateral sclerosis carriers of not fully penetrant SOD1 mutations. Amyotroph. Lateral Scler. Frontotemporal Degener. 19, 93-101.</Citation><ArticleIdList><ArticleId IdType="pubmed">28859526</ArticleId></ArticleIdList></Reference><Reference><Citation>Costenla A.R., Di&#xf3;genes M.J., Canas P.M., Rodrigues R.J., Nogueira C., Maroco J., Agostinho P.M., Ribeiro J.A., Cunha R.A. and de Mendon&#xe7;a A. (2011). Enhanced role of adenosine A2A receptors in the modulation of LTP in the rat hippocampus upon ageing. Eur. J. Neurosci. 34, 12-21.</Citation><ArticleIdList><ArticleId IdType="pubmed">21615561</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Ovidio F., d&#x2019;Errico A., Carn&#xe0; P., Calvo A., Costa G. and Chi&#xf2; A. (2018). The role of pre-morbid diabetes on developing amyotrophic lateral sclerosis. Eur. J. Neurol. 25, 164-170</Citation><ArticleIdList><ArticleId IdType="pubmed">28921834</ArticleId></ArticleIdList></Reference><Reference><Citation>Daddona P.E. and Kelley W.N. (1977). Human adenosine deaminase. Purification and subunit structure. J. Biol. Chem. 252, 110-115.</Citation><ArticleIdList><ArticleId IdType="pubmed">13062</ArticleId></ArticleIdList></Reference><Reference><Citation>de Jong S., Huisman M., Sutedja N., van der Kooi A., de Visser M., Schelhaas J., van der Schouw Y., Veldink J. and van den Berg L. (2012). Endogenous female reproductive hormones and the risk of amyotrophic lateral sclerosis. J. Neurol. 260, 507-512.</Citation><ArticleIdList><ArticleId IdType="pubmed">22972621</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Y., Gam J., French J.B., Zhao H., An S. and Benkovic S.J. (2012). Mapping protein-protein proximity in the purinosome. J. Biol. Chem. 287, 36201-36207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3476287</ArticleId><ArticleId IdType="pubmed">22955281</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xe9;rijard B., Hibi M., Wu I.H., Barrett T., Su B., Deng T., Karin M. and Davis R.J. (1994). JNK1: A protein kinase stimulated by UV light and ha-ras that binds and phosphorylates the c-Jun activation domain. Cell 76, 1025-1037.</Citation><ArticleIdList><ArticleId IdType="pubmed">8137421</ArticleId></ArticleIdList></Reference><Reference><Citation>Dettori I., Gaviano L., Ugolini F., Lana D., Bulli I., Magni G., Rossi F., Giovannini M.G. and Pedata F. (2021). Protective effect of adenosine A2B receptor agonist, BAY60-6583, against transient focal brain ischemia in rat. Front. Pharmacol. 11, 588757</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7905306</ArticleId><ArticleId IdType="pubmed">33643036</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixon A.K., Gubitz A.K., Sirinathsinghji D.J.S., Richardson P.J. and Freeman T.C. (1996). Tissue distribution of adenosine receptor mRNAs in the rat. Br. J. Pharmacol. 118, 1461-1468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1909676</ArticleId><ArticleId IdType="pubmed">8832073</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolezal T., Dolezelova E., Zurovec M. and Bryant P.J. (2005). A role for adenosine deaminase in drosophila larval development. PLoS Biol. 3, 201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1135298</ArticleId><ArticleId IdType="pubmed">15907156</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolphin A.C., Forda S.R. and Scott R.H. (1986). Calcium-dependent currents in cultured rat dorsal root ganglion neurones are inhibited by an adenosine analogue. J. Physiol. 373, 47-61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1182524</ArticleId><ArticleId IdType="pubmed">2427698</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong R.P., Kameoka J., Hegen M., Tanaka T., Xu Y., Schlossman S.F. and Morimoto C. (1996). Characterization of adenosine deaminase binding to human CD26 on t cells and its biologic role in immune response. J. Immunol. 156, 1349-1355.</Citation><ArticleIdList><ArticleId IdType="pubmed">8568233</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunwiddie T.V. and Masino S.A. (2001). The role and regulation of adenosine in the central nervous system. Annu. Rev. Neurosci. 24, 31-55.</Citation><ArticleIdList><ArticleId IdType="pubmed">11283304</ArticleId></ArticleIdList></Reference><Reference><Citation>Dusing M.R. and Wiginton D.A. (1994). Sp1 is essential for both enhancer-mediated and basal activation of the TATA-less human adenosine deaminase promoter. Nucleic. Acids Res. 22, 669-677.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC307859</ArticleId><ArticleId IdType="pubmed">8127716</ArticleId></ArticleIdList></Reference><Reference><Citation>Eguchi R., Kitano T. and Otsuguro K. (2020). Fibroblast growth factor 2 upregulates ecto-5&#x2032;-nucleotidase and adenosine deaminase via MAPK pathways in cultured rat spinal cord astrocytes. Purinergic Signal. 16, 519-527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7855126</ArticleId><ArticleId IdType="pubmed">33025426</ArticleId></ArticleIdList></Reference><Reference><Citation>El Yacoubi M., Ledent C., M&#xe9;nard J-F., Parmentier M., Costentin J. and Vaugeois J-M. (2000). The stimulant effects of caffeine on locomotor behaviour in mice are mediated through its blockade of adenosine A2A receptors. Br. J. Pharmacol. 129, 1465-1473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1571962</ArticleId><ArticleId IdType="pubmed">10742303</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang L., Teuchert M., Huber-Abel F., Schattauer D., Hendrich C., Dorst J., Zettlmeissel H., Wlaschek M., Scharffetter-Kochanek K., Kapfer T., Tumani H., Ludolph A.C. and Brettschneider J. (2010). MMP-2 and MMP-9 are elevated in spinal cord and skin in a mouse model of ALS. J. Neurol. Sci. 294, 51-56.</Citation><ArticleIdList><ArticleId IdType="pubmed">20441996</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang P., Li X., Luo JJ., Wang H. and Yang X-F. (2013). A double-edged sword: Uric acid and neurological disorders. Brain Disord. Ther. 2, 109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3914730</ArticleId><ArticleId IdType="pubmed">24511458</ArticleId></ArticleIdList></Reference><Reference><Citation>Farg M.A., Konopka A., Soo K.Y., Ito D. and Atkin J.D. (2017). The DNA damage response (DDR) is induced by the C9orf72 repeat expansion in amyotrophic lateral sclerosis. Hum. Mol. Genet. 26, 2882-2896.</Citation><ArticleIdList><ArticleId IdType="pubmed">28481984</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraiuolo L., Higginbottom A., Heath P.R., Barber S., Greenald D., Kirby J. and Shaw P.J. (2011). Dysregulation of astrocytemotoneuron cross-talk in mutant superoxide dismutase 1-related amyotrophic lateral sclerosis. Brain 134, 2627-2641.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170534</ArticleId><ArticleId IdType="pubmed">21908873</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraiuolo L., Meyer K., Sherwood T.W., Vick J., Likhite S., Frakes A., Miranda C.J., Braun L., Heath P.R., Pineda R., Beattie C.E., Shaw P.J., Askwith C.C., McTigue D. and Kaspar B.K. (2016). Oligodendrocytes contribute to motor neuron death in ALS via SOD1-dependent mechanism. Proc. Natl. Acad. Sci. USA 113, 6496-6505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5081600</ArticleId><ArticleId IdType="pubmed">27688759</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrante R.J., Browne S.E., Shinobu L.A., Bowling A.C., Baik M.J., MacGarvey U., Kowall N.W., Brown R.H. and Beal M.F. (1997). Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J. Neurochem. 69, 2064-2074.</Citation><ArticleIdList><ArticleId IdType="pubmed">9349552</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueroa-Romero C., Hur J., Bender D.E., Delaney C.E., Cataldo M.D., Smith A.L., Yung R., Ruden D.M., Callaghan B.C. and Feldman E.L. (2012). Identification of epigenetically altered genes in sporadic amyotrophic lateral sclerosis. PLoS One 7, 52672</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530456</ArticleId><ArticleId IdType="pubmed">23300739</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer D., Van der Weyden M.B., Snyderman R. and Kelley W.N. (1976). A role for adenosine deaminase in human monocyte maturation. J. Clin. Invest. 58, 399-407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC333195</ArticleId><ArticleId IdType="pubmed">956374</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzmaurice P.S., Shaw I.C., Kleiner H.E., Miller R.T., Monks T.J., Lau S.S., Mitchell J.D. and Lynch P.G . (1996). Evidence for DNA damage in amyotrophic lateral sclerosis. Muscle Nerve 19, 797-798.</Citation><ArticleIdList><ArticleId IdType="pubmed">8609941</ArticleId></ArticleIdList></Reference><Reference><Citation>Flinn A.M. and Gennery A.R. (2018). Adenosine deaminase deficiency: A review. Orphanet J. Rare Dis. 13, 65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5916829</ArticleId><ArticleId IdType="pubmed">29690908</ArticleId></ArticleIdList></Reference><Reference><Citation>Florian C., Vecsey C.G., Halassa M.M., Haydon P.G. and Abel T. (2011). Astrocyte-derived adenosine and A1 receptor activity contribute to sleep loss-induced deficits in hippocampal synaptic plasticity and memory in mice. J. Neurosci. 31, 6956-6962.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3140051</ArticleId><ArticleId IdType="pubmed">21562257</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox I.H. and Kelley W.N. (1978). The role of adenosine and 2&#x2019;- deoxyadenosine in mammalian cells. Annu. Rev. Biochem. 47, 655- 686.</Citation><ArticleIdList><ArticleId IdType="pubmed">209731</ArticleId></ArticleIdList></Reference><Reference><Citation>Franco R., Casad&#xf3; V., Ciruela F., Saura C., Mallol J., Canela E.I. and Lluis C. (1997). Cell surface adenosine deaminase: Much more than an ectoenzyme. Prog. Neurobiol. 52, 283-294.</Citation><ArticleIdList><ArticleId IdType="pubmed">9247966</ArticleId></ArticleIdList></Reference><Reference><Citation>Fredholm B.B. (2007). Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ. 14, 1315- 1323.</Citation><ArticleIdList><ArticleId IdType="pubmed">17396131</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum B.D., Chitta R., High A.A. and Taylor J.P. (2010). Global analysis of TDP-43 interacting proteins reveals strong association with RNA splicing and translation machinery. J. Proteome Res. 9, 1104-1120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2897173</ArticleId><ArticleId IdType="pubmed">20020773</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Segura L.M., Azcoitia I. and Don Carlos L.L. (2001). Neuroprotection by estradiol. Prog. Neurobiol. 63, 29-60.</Citation><ArticleIdList><ArticleId IdType="pubmed">11040417</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg N., Kasapcopur O., Foster J., Barut K., Tekin A., K&#x131;z&#x131;lk&#x131;l&#x131;&#xe7; O. and Tekin M. (2014). Novel adenosine deaminase 2 mutations in a child with a fatal vasculopathy. Eur. J. Pediatr. 173, 827-830.</Citation><ArticleIdList><ArticleId IdType="pubmed">24737293</ArticleId></ArticleIdList></Reference><Reference><Citation>Garton F.C., Benyamin B., Zhao Q., Liu Z., Gratten J., Henders A.K., Zhang Z-H., Edson J., Furlong S., Morgan S., Heggie S., Thorpe K., Pfluger C., Mather K.A., Sachdev P.S., McRae A.F., Robinson M.R., Shah S., Visscher P.M., Mangelsdorf M., Henderson R.D., Wray N.R. and McCombe P.A. (2017). Whole exome sequencing and DNA methylation analysis in a clinical amyotrophic lateral sclerosis cohort. Mol. Genet. Genomic Med. 5, 418-428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5511806</ArticleId><ArticleId IdType="pubmed">28717666</ArticleId></ArticleIdList></Reference><Reference><Citation>Geffner M.E., Stiehm E.R., Stephure D. and Cowan M.J. (1986). Probable autoimmune thyroid disease and combined immunodeficiency disease. Am. J. Dis. Child. 140, 1194-1196.</Citation><ArticleIdList><ArticleId IdType="pubmed">3490177</ArticleId></ArticleIdList></Reference><Reference><Citation>Geraldo A.F., Caorsi R., Tortora D., Gandolfo C., Ammendola R., Alessio M., Conti G., Insalaco A., Pastore S., Martino S., Ceccherini I., Signa S., Gattorno M., Rossi A. and Severino M. (2021). Widening the neuroimaging features of adenosine deaminase 2 deficiency. Am. J. Neuroradiol. 42, 975-979</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8115359</ArticleId><ArticleId IdType="pubmed">33632736</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerou M., Hall B., Woof R., Allsop J., Kolb S.J., Meyer K., Shaw P.J. and Allen S.P. (2021). Amyotrophic lateral sclerosis alters the metabolic aging profile in patient derived fibroblasts. Neurobiol. Aging 105, 64-77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8346650</ArticleId><ArticleId IdType="pubmed">34044197</ArticleId></ArticleIdList></Reference><Reference><Citation>Giblett E.R., Anderson J.E., Cohen F., Pollara B. and Meuwissen H.J. (1972). Adenosine deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 300, 1067-1069</Citation><ArticleIdList><ArticleId IdType="pubmed">4117384</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerrero E.N., Mitra J., Wang H., Rangaswamy S., Hegde P.M., Basu P., Rao K.S. and Hegde M.L. (2019). Amyotrophic lateral sclerosisassociated TDP-43 mutation Q331K prevents nuclear translocation of XRCC4-DNA ligase 4 complex and is linked to genome damagemediated neuronal apoptosis. Hum. Mol. Genet. 28, 2459-2476.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6659010</ArticleId><ArticleId IdType="pubmed">31067307</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamzeiy H., Sava&#x15f; D., Tunca C., &#x15e;en N.E., Eken A.G., &#x15e;ahbaz I., Calini D., Tiloca C., Ticozzi N., Ratti A., Silani V. and Ba&#x15f;ak A.N. (2018). Elevated global DNA methylation is not exclusive to amyotrophic lateral sclerosis and is also observed in spinocerebellar ataxia types 1 and 2. Neurodegener. Dis. 18, 38-48.</Citation><ArticleIdList><ArticleId IdType="pubmed">29428949</ArticleId></ArticleIdList></Reference><Reference><Citation>Han J., Lee J-D., Bibbs L. and Ulevitch R.J. (1994). A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 265, 808-811.</Citation><ArticleIdList><ArticleId IdType="pubmed">7914033</ArticleId></ArticleIdList></Reference><Reference><Citation>Heitzer M., Kaiser S., Kanagaratnam M., Zendedel A., Hartmann P., Beyer C. and Johann S. (2017). Administration of 17&#x3b2;-estradiol improves motoneuron survival and down-regulates inflammasome activation in male SOD1(G93A) ALS mice. Mol. Neurobiol. 54, 1-15.</Citation><ArticleIdList><ArticleId IdType="pubmed">27957680</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel J-S., Engelhardt J-I., Sikl&#xf3;s L., Simpson E-P., Kim S-H., Pan T., Goodman J-C., Siddique T., Beers D-R. and Appel S-H. (2004). Presence of dendritic cells, MCP-1, and activated microglia/ macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann. Neurol. 55, 221-235.</Citation><ArticleIdList><ArticleId IdType="pubmed">14755726</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel J-S., Beers D-R., Wen S., Rivera A-L., Toennis K-M., Appel J-E., Zhao W., Moore D-H., Powell S-Z. and Appel S-H. (2013). Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol. Med. 5, 64-79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3569654</ArticleId><ArticleId IdType="pubmed">23143995</ArticleId></ArticleIdList></Reference><Reference><Citation>Henney C-S. and Lichtenstein L-M. (1971). The role of cyclic AMP in the cytolytic activity of lymphocytes. J. Immunol. 107, 610-612.</Citation><ArticleIdList><ArticleId IdType="pubmed">4328013</ArticleId></ArticleIdList></Reference><Reference><Citation>Hershfield M.S. (2003). Genotype is an important determinant of phenotype in adenosine deaminase deficiency. Curr. Opin. Immunol. 15, 571-577.</Citation><ArticleIdList><ArticleId IdType="pubmed">14499267</ArticleId></ArticleIdList></Reference><Reference><Citation>Hettinger J.A., Liu X. and Holden J.J. (2008). The G22A polymorphism of the ADA gene and susceptibility to autism spectrum disorders. J. Autism Dev. Disord. 38, 14-19.</Citation><ArticleIdList><ArticleId IdType="pubmed">17340203</ArticleId></ArticleIdList></Reference><Reference><Citation>Hideyama T., Yamashita T., Aizawa H., Tsuji S., Kakita A., Takahashi H. and Kwak S. (2012). Profound downregulation of the RNA editing enzyme ADAR2 in ALS spinal motor neurons. Neurobiol. Dis. 45, 1121-1128.</Citation><ArticleIdList><ArticleId IdType="pubmed">22226999</ArticleId></ArticleIdList></Reference><Reference><Citation>Higelin J., Catanese A., Semelink-Sedlacek LL., Oeztuerk S., Lutz AK., Bausinger J., Barbi G, Speit G., Andersen PM., Ludolph AC., Demestre M., Boeckers TM. (2018). NEK1 loss-of-function mutation induces DNA damage accumulation in ALS patient-derived motoneurons. Stem Cell Res. 30, 150-162.</Citation><ArticleIdList><ArticleId IdType="pubmed">29929116</ArticleId></ArticleIdList></Reference><Reference><Citation>Higelin J., Demestre M., Putz S., Delling J.P., Jacob C., Lutz A-K., Bausinger J., Huber A-K, Klingenstein M., Barbi G., Speit G., Huebers A., Weishaupt JH., Hermann A., Liebau S., Ludolph A.C., Boeckers A.M. (2016). FUS mislocalization and vulnerability to DNA damage in ALS patients derived HiPSCs and aging motoneurons. Front. Cell. Neurosci. 10, 290.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5183648</ArticleId><ArticleId IdType="pubmed">28082870</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirschhorn R., Yang D.R. and Israni A. (1994). An Asp8Asn substitution results in the adenosine deaminase (ADA) genetic polymorphism (ADA 2 allozyme): occurrence on different chromosomal backgrounds and apparent intragenic crossover. Ann. Hum. Genet. 58, 1-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">8031011</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirschhorn R., Paageorgiou PS., Kesarwala H.H. and Taft L.T. (1980). Amerioration of neurologic abnormalities after &#x2018;enzyme replacement&#x2019; in adenosine deaminase deficiency. N. Engl. J. Med. 303, 377-380.</Citation><ArticleIdList><ArticleId IdType="pubmed">6156414</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xf6;nig M., Albert M.H., Schulz A., Sparber-Sauer M., Sch&#xfc;tz C., Belohradsky B., G&#xfc;ng&#xf6;r T., Rojewski M.T., Bode H., Pannicke U., Lippold D., Schwarz K., Debatin K-M., Hershfield M.S. and Friedrich W. (2007). Patients with adenosine deaminase deficiency surviving after hematopoietic stem cell transplantation are at high risk of CNS complications. Blood 109, 3595-3602.</Citation><ArticleIdList><ArticleId IdType="pubmed">17185467</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoshino T., Yamada K., Masuoka K., Tsuboi I., Itoh K., Nonaka K. and Oizumi K. (1994). Elevated adenosine deaminase activity in the serum of patients with diabetes mellitus. Diabetes Res. Clin. Pract. 25, 97-102.</Citation><ArticleIdList><ArticleId IdType="pubmed">7821197</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang W., Xu Y., Zhang Y., Zhang P., Zhang Q., Zhang Z. and Xu F. (2019). Metabolomics-driven identification of adenosine deaminase as therapeutic target in a mouse model of Parkinson&#x2019;s disease. J. Neurochem. 150, 282-295.</Citation><ArticleIdList><ArticleId IdType="pubmed">31121068</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Z.L., Zhang Z. and Qu W.M. (2014). Roles of adenosine and its receptors in sleep-wake regulation. Int. Rev. Neurobiol. 119, 349- 371.</Citation><ArticleIdList><ArticleId IdType="pubmed">25175972</ArticleId></ArticleIdList></Reference><Reference><Citation>Ihara Y., Nobukuni K, Takata H. and Hayabara T. (2005). Oxidative stress and metal content in blood and cerebrospinal fluid of amyotrophic lateral sclerosis patients with and without a Cu, Znsuperoxide dismutase mutation. Neurol. Res. 27, 105-108.</Citation><ArticleIdList><ArticleId IdType="pubmed">15829169</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishioh M., Nozu T., Igarashi S., Tanabe H., Kumei S., Ohhira M., Takakusaki K. and Okumura T. (2021). Activation of central adenosine A2B receptors mediate brain ghrelin-induced improvement of intestinal barrier function through the vagus nerve in rats. Exp. Neurol. 341, 113708.</Citation><ArticleIdList><ArticleId IdType="pubmed">33771554</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkins T., Rabson A.R., Nurse G.T., Lane A.B. and Hopkinson D.A. (1976). Deficiency of adenosine deaminase not associated with severe combined immunodeficiency. J. Pediatr. 89, 732-736.</Citation><ArticleIdList><ArticleId IdType="pubmed">978319</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston Jr. R.B., Keele Jr. B.B., Misra H.P., Lehmeyer J.E., Webb L.S., Baehner R.L. and RaJagopalan K.V. (1975). The role of superoxide anion generation in phagocytic bactericidal activity. Studies with normal and chronic granulomatous disease leukocytes. J. Clin. Invest. 55, 1357-1372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC301891</ArticleId><ArticleId IdType="pubmed">166094</ArticleId></ArticleIdList></Reference><Reference><Citation>Jost C.A., Marin M.C. and Kaelin W.G. (1997). P73 is a human p53- related protein that can induce apoptosis. Nature 389, 191-194.</Citation><ArticleIdList><ArticleId IdType="pubmed">9296498</ArticleId></ArticleIdList></Reference><Reference><Citation>Jurkowitz M.S., Litsky M.L., Browning M.J. and Hohl C.M. (1998). Adenosine, inosine and guanosine protect glial cells during glucose deprivation and mitochondrial inhibition: Correlation between protection and ATP preservation. J. Neurochem. 71, 535-548.</Citation><ArticleIdList><ArticleId IdType="pubmed">9681443</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaghad M., Bonnet H., Yang A., Creancier L., Biscan J-C., Valent A., Minty A., Chalon P., Lelias J.M., Dumont X., Ferrara P., McKeon F. and Caput D. (1997). Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90, 809-819.</Citation><ArticleIdList><ArticleId IdType="pubmed">9288759</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalman L., Lindegren M.L., Kobrynski L., Vogt R., Hannon H., Howard JT. and Buckley R. (2004). Mutations in genes required for T-cell development: IL7R, CD45, IL2RG, JAK3, RAG1, RAG2, ARTEMIS and ADA and severe combined immunodeficiency: HuGE review. Genet. Med. 6, 16-26.</Citation><ArticleIdList><ArticleId IdType="pubmed">14726805</ArticleId></ArticleIdList></Reference><Reference><Citation>Kameoka J., Tanaka T., Nojima Y., Schlossman S.F. and Morimoto C. (1993). Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science 261, 466-469.</Citation><ArticleIdList><ArticleId IdType="pubmed">8101391</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasai H. and Nishimura S. (1984). Hydroxylation of deoxyguanosine at the C-8 poistion by polyphenols and aminophenols in the presence of hydrogen peroxide and ferric ion. Gan 75, 565-566.</Citation><ArticleIdList><ArticleId IdType="pubmed">6468841</ArticleId></ArticleIdList></Reference><Reference><Citation>Kathiresan K., Saravanakumar K., Sahu S.K. and Sivasankaran M. (2013). Adenosine deaminase production by an endophytic bacterium (lysinibacillus sp.) from avicennia marina. 3 Biotech. 4, 235-239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4026454</ArticleId><ArticleId IdType="pubmed">28324425</ArticleId></ArticleIdList></Reference><Reference><Citation>Keizman D., Ish-Shalom M., Berliner S., Maimon N., Vered Y., Artamonov I., Tsehori J., Nefussy B. and Drory V.E. (2009). Low uric acid levels in serum of patients with ALS: further evidence for oxidative stress?. J. Neurol. Sci. 285, 95-99.</Citation><ArticleIdList><ArticleId IdType="pubmed">19552925</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenna K.P., van Doormaal P.T.C., Dekker A.M., Ticozzi N., Kenna B.J., Diekstra F.P., van Rheenen W., van Eijk K.R., Jones A.R., Keagle P., Shatunov A., Sproviero W., Smith B.N., van Es M.A., Topp S.D., Kenna A., Miller J.W., Fallini C., Tiloca C., McLaughlin R.L., Vance C., Troakes C., Colombrita C., Mora G., Calvo A., Verde F., AlSarraj S., King A., Calini D., de Belleroche J., Baas F., van der Kooi A.J., de Visser M., Ten Asbroek A.L., Sapp P.C., McKenna-Yasek D., Polak M., Asress S., Mu&#xf1;oz-Blanco J.L., Strom T.M., Meitinger T., Morrison K.E., SLAGEN Consortium., Lauria G., Williams K.L., Leigh P.N., Nicholson G.A., Blair I.P., Leblond C.S., Dion P.A., Rouleau G.A., Pall H., Shaw P.J., Turner M.R., Talbot K., Taroni F., Boylan K.B., Van Blitterswijk M., Rademakers R., Esteban-P&#xe9;rez J., Garc&#xed;a-Redondo A., Van Damme P., Robberecht W., Chio A., Gellera C., Drepper C., Sendtner M., Ratti A., Glass J.D., Mora J.S., Basak N.A., Hardiman O., Ludolph A.C., Andersen P.M., Weishaupt J.H., Brown Jr R.H., Al-Chalabi A., Silani V., Shaw C.E., van den Berg L.H., Veldink J.H. and Landers J.E. (2016). NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. Nat. Genet. 48, 1037-1042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5560030</ArticleId><ArticleId IdType="pubmed">27455347</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim B.W., Jeong Y.E., Wong M. and Martin L.J. (2020). DNA damage accumulates and responses are engaged in human ALS brain and spinal motor neurons and DNA repair is activatable in IPSC-derived motor neurons with SOD1 mutations. Acta Neuropathol. Commun. 8, 7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6995159</ArticleId><ArticleId IdType="pubmed">32005289</ArticleId></ArticleIdList></Reference><Reference><Citation>Kioumourtzoglou M.A., Rotem R.S., Seals R.M., Gredal O., Hansen J. and Weisskopf M.G. (2015). Diabetes mellitus, obesity and diagnosis of amyotrophic lateral sclerosis a population-based study. JAMA Neurol. 72, 905-911.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4975611</ArticleId><ArticleId IdType="pubmed">26030836</ArticleId></ArticleIdList></Reference><Reference><Citation>Klemann C.J.H.M., Visser J.E., Van Den Bosch L., Martens G.J.M. and Poelmans G. (2018). Integrated molecular landscape of amyotrophic lateral sclerosis provides insights into disease etiology. Brain Pathol. 28, 203-211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8028446</ArticleId><ArticleId IdType="pubmed">28035716</ArticleId></ArticleIdList></Reference><Reference><Citation>Kok J.R., Palminha N.M., Souza C.D.S., El-Khamisy S.F. and Ferraiuolo L. (2021). DNA damage as a mechanism of neurodegeneration in ALS and a contributor to astrocyte toxicity. Cell. Mol. Life Sci. 78, 5707-5729.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8316199</ArticleId><ArticleId IdType="pubmed">34173837</ArticleId></ArticleIdList></Reference><Reference><Citation>Konopka A., Whelan D.R., Jamali M.S., Perri E., Shahheydari H., Toth R.P., Parakh S., Robinson T., Cheong A., Mehta P., Vidal M., Ragagnin A.M.G., Khizhnyak I., Jagaraj C.J., Galper J., Grima N., Deva A., Shadfar S., Nicholson G.A., Yang S., Cutts S.M., Horejsi Z., Bell T.D.M., Walker A.K., Blair I.P. and Atkin J.D. (2020). Impaired NHEJ repair in amyotrophic lateral sclerosis is associated with TDP-43 mutations. Mol. Neurodegener. 15, 51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7488163</ArticleId><ArticleId IdType="pubmed">32907630</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurtul N., Pence S., Akarsu E., Kocoglu H., Aksoy Y. and Aksoy H. (2004). Adenosine deaminase activity in the serum of type 2 diabetic patients. Acta Medica 47, 33-35.</Citation><ArticleIdList><ArticleId IdType="pubmed">15168879</ArticleId></ArticleIdList></Reference><Reference><Citation>Kutryb-Zajac B., Mierzejewska P., Slominska E.M. and Smolenski R.T. (2020). Therapeutic perspectives of adenosine deaminase inhibition in cardiovascular diseases. Molecules 25, 4652.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7587364</ArticleId><ArticleId IdType="pubmed">33053898</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavigueur A., La Branche H., Kornblihtt A.R. and Chabot B. (1993). A splicing enhancer in the human fibronectin alternate ED1 exon interacts with SR proteins and stimulates U2 SnRNP binding. Genes Dev. 7, 2405-2417.</Citation><ArticleIdList><ArticleId IdType="pubmed">8253386</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee K., Li B., Xi X., Suh Y. and Martin R.J. (2005). Role of neuronal energy status in the regulation of adenosine 5&#x2019;-monophosphateactivated protein kinase, orexigenic neuropeptides expression and feeding behavior. Endocrinology 146, 3-10.</Citation><ArticleIdList><ArticleId IdType="pubmed">15375032</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J.G., Kang D.G., Yu J.R., Kim Y., Kim J., Koh G. and Lee D. (2011). Changes in adenosine deaminase activity in patients with type 2 diabetes mellitus and effect of DPP-4 inhibitor treatment on ADA activity. Diabetes Metab. J. 35, 149-158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3122899</ArticleId><ArticleId IdType="pubmed">21738897</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee P-Y., Huang Y., Zhou Q., Schnappauf O., Hershfield M-S., Li Y., Ganson N-J., Sampaio Moura N., Delmonte O-M., Stone S-S., Rivkin M-J., Pai S-Y., Lyons T., Sundel R-P., Hsu V-W., Notarangelo L-D., Aksentijevich I. and Nigrovic P-A. (2018). Disrupted N-linked glycosylation as a disease mechanism in deficiency of ADA2. J. Allergy. Clin. Immunol. 142, 1363-1365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6175612</ArticleId><ArticleId IdType="pubmed">29936104</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Song M., Moh S., Kim H. and Kim D-H. (2019). Cytoplasmic restriction of mutated SOD1 impairs the DNA repair process in spinal cord neurons. Cells 8, 1502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6952796</ArticleId><ArticleId IdType="pubmed">31771229</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Gonzalez R., Lu Y., Gendron TF., Karydas A., Tran H., Yang D., Petrucelli L., Miller B.L., Almeida S. and Gao F.B. (2016). Poly(GR) in C9ORF72-related ALS/FTD compromises mitochondrial function and increases oxidative stress and DNA damage in IPSC-derived motor neurons. Neuron 92, 383-391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5111366</ArticleId><ArticleId IdType="pubmed">27720481</ArticleId></ArticleIdList></Reference><Reference><Citation>Macek T.A., Schaffhauser H. and Conn P.J. (1998). Protein kinase C and A3 adenosine receptor activation inhibit presynaptic metabotropic glutamate receptor (MGluR) function and uncouple MGluRs from GTP-binding proteins. J. Neurosci. 18, 6138-6146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793218</ArticleId><ArticleId IdType="pubmed">9698308</ArticleId></ArticleIdList></Reference><Reference><Citation>Majounie E., Renton A.E., Mok K., Dopper E.G.P., Waite A., Rollinson S., Chi&#xf2; A., Restagno G., Nicolaou N., Simon-Sanchez J., van Swieten J.C., Abramzon Y., Johnson J.O., Sendtner M., Pamphlett R., Orrell R.W., Mead S., Sidle K.C., Houlden H., Rohrer J.D., Morrison K.E., Pall H., Talbot K., Ansorge O., Chromosome 9- ALS/FTD Consortium., French research network on FTLD/FTLD/ALS., ITALSGEN Consortium., Hernandez D.G., Arepalli S., Sabatelli M., Mora G., Corbo M., Giannini F., Calvo A., Englund E., Borghero G., Floris G.L., Remes A.M., Laaksovirta H., McCluskey L., Trojanowski J.Q., Van Deerlin V.M., Schellenberg G.D., Nalls M.A., Drory VE., Lu C.S., Yeh T.H., Ishiura H., Takahashi Y., Tsuji S., Le Ber I., Brice A., Drepper C., Williams N., Kirby J., Shaw P., Hardy J., Tienari P.J., Heutink P., Morris H.R., Pickering-Brown S. and Traynor B.J. (2012). Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: A crosssectional study. Lancet Neurol. 11, 323-330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322422</ArticleId><ArticleId IdType="pubmed">22406228</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantovani S., Garbelli S., Pasini A., Alimonti D., Perotti C., Melazzini M., Bendotti C. and Mora G. (2009). Immune system alterations in sporadic amyotrophic lateral sclerosis patients suggest an ongoing neuroinflammatory process. J. Neuroimmunol. 210, 73-79.</Citation><ArticleIdList><ArticleId IdType="pubmed">19307024</ArticleId></ArticleIdList></Reference><Reference><Citation>Maor-Nof M., Shipony Z., Lopez-Gonzalez R., Nakayama L., Zhang YJ., Couthouis J., Blum J.A., Castruita P.A., Linares G.R., Ruan K., Ramaswami G., Simon D.J., Nof A., Santana M., Han K., SinnottArmstrong N., Bassik M.C., Geschwind D.H., Tessier-Lavigne M., Attardi L.D., Lloyd T.E., Ichida J.K., Gao F.B., Greenleaf W.J., Yokoyama J.S., Petrucelli L. and Gitler A.D. (2021). p53 Is a central regulator driving neurodegeneration caused by C9orf72 Poly (PR). Cell 184, 689-708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7886018</ArticleId><ArticleId IdType="pubmed">33482083</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariosa D., Kamel F., Bellocco R., Ye W.and Fang F. (2015). Association between diabetes and amyotrophic lateral sclerosis in sweden. Eur. J. Neurol. 22, 1436-1442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4506907</ArticleId><ArticleId IdType="pubmed">25600257</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall C.B., Beeler J.S., Lehmann B.D., Gonzalez-Ericsson P., Sanchez V., Sanders M.E., Boyd K.L. and Pietenpol J.A . (2021). Tissue-specific expression of p73 and p63 isoforms in human tissues. Cell Death Dis. 12, 1-10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8316356</ArticleId><ArticleId IdType="pubmed">34315849</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;n M., Huguet J., Centelles J.J. and Franco R. (1995). Expression of ecto-adenosine deaminase and CD26 in human T cells triggered by the TCR-CD3 complex. possible role of adenosine deaminase as costimulatory molecule. J. Immunol. 155, 4630-4663.</Citation><ArticleIdList><ArticleId IdType="pubmed">7594462</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Navio J.M., Casanova V., Pacheco R., Naval-Macabuhay I., Climent N., Garcia F., Gatell J.M., Mallol J., Gallart T., Lluis C. and Franco R. (2011). Adenosine deaminase potentiates the generation of effector, memory and regulatory CD4+ T cells. J. Leuko. Biol. 89, 127-136.</Citation><ArticleIdList><ArticleId IdType="pubmed">20959412</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayeda A., Helfman D.M. and Krainer A.R. (1993). Modulation of exon skipping and inclusion by heterogeneous nuclear ribonucleoprotein A1 and pre-mRNA splicing factor SF2/ASF. Mol. Cell Biol. 13, 2993- 3001.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC359692</ArticleId><ArticleId IdType="pubmed">8474457</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer P.L., Itagaki S. and McGeer E.G. (1988). Expression of the histocompatibility glycoprotein HLA-DR in neurological disease. Acta Neuropathol. 76, 550-557.</Citation><ArticleIdList><ArticleId IdType="pubmed">2974227</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R., Flynn D.L., Pitout IL., Fletcher S., Wilton SD. and Akkari P.A. (2019). ALS genetics, mechanisms and therapeutics: Where are we now? Front. Neurosci. 13, 1310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Melcher T., Maas S., Herb A., Sprengel R., Seeburg P.H. and Higuchi M. (1996). A mammalian RNA editing enzyme. Nature 379, 460-464.</Citation><ArticleIdList><ArticleId IdType="pubmed">8559253</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitra J., Guerrero E.N., Hegde P.M., Liachko N.F., Wang H., Vasquez V., Gao J., Pandey A., Taylor J.P., Kraemer B.C., Wu P., Boldogh I., Garruto R.M., Mitra S., Rao K.S. and Hegde M.L. (2019). Motor neuron disease-associated loss of nuclear TDP-43 is linked to DNA double-strand break repair defects. Proc. Natl. Acad. Sci. USA 116, 4696-4705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6410842</ArticleId><ArticleId IdType="pubmed">30770445</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto H., Santella R.M., Liu X., Bogdanov M., Zipprich J., Wu H-C., Mahata J., Kilty M., Bednarz K., Bell D., Gordon P.H., Hornig M., Mehrazin M., Naini A., Beal M.F. and Factor-Litvak P. (2008). Oxidative stress biomarkers in sporadic ALS. Amyotroph. Lateral Scler. 9, 177-183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4332387</ArticleId><ArticleId IdType="pubmed">18574762</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore S., Alsop E., Lorenzini I., Starr A., Rabichow B.E., Mendez E., Levy J.L., Burciu C., Reiman R., Chew J., Belzil V.V., Dickson D.W, Robertson J., Staats K.A., Ichida J.K., Petrucelli L., Van KeurenJensen K. and Sattler R. (2019). ADAR2 mislocalization and widespread RNA editing aberrations in C9orf72-mediated ALS/FTD. Acta Neuropathol. 138, 49-65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6750285</ArticleId><ArticleId IdType="pubmed">30945056</ArticleId></ArticleIdList></Reference><Reference><Citation>Morahan J.M., Yu B., Trent R.J. and Pamphlett R . (2009). A genomewide analysis of brain DNA methylation identifies new candidate genes for sporadic amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 10, 418-429.</Citation><ArticleIdList><ArticleId IdType="pubmed">19922134</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno E., Canet J., Gracia E., Llu&#xed;s C., Mallol J., Canela E.I., Cort&#xe9;s A. and Casad&#xf3; V. (2018). Molecular evidence of adenosine deaminase linking adenosine A2A receptor and CD26 proteins. Front. Pharmacol. 9, 106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5818423</ArticleId><ArticleId IdType="pubmed">29497379</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K., Weng S-M., Arzberger T., May S., Rentzsch K., Kremmer E., Schmid B., Kretzschmar HA., Cruts M., Van Broeckhoven C., Haass C. and Edbauer D. (2013). The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science 339, 1335-1338.</Citation><ArticleIdList><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison D.K. (2012). MAP kinase pathways. Cold Spring Harb. Perspect. Biol. 4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3536342</ArticleId><ArticleId IdType="pubmed">23125017</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulder D., Kurland L., Offord K. and Beard C. (1986). Familial adult motor neuron disease: Amyotrophic lateral sclerosis. Neurology 36, 511-517.</Citation><ArticleIdList><ArticleId IdType="pubmed">3960325</ArticleId></ArticleIdList></Reference><Reference><Citation>Murata T., Ohtsuka C. and Terayama Y. (2008). Increased mitochondrial oxidative damage and oxidative DNA damage contributes to the neurodegenerative process in sporadic amyotrophic lateral sclerosis. Free Radic. Res. 42, 221-225.</Citation><ArticleIdList><ArticleId IdType="pubmed">18344116</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray-Zmijewski F., Lane DP. and Bourdon J-C. (2006). p53/p63/p73 isoforms: An orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ. 13, 962-972.</Citation><ArticleIdList><ArticleId IdType="pubmed">16601753</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy J.I., LaBella L.A., Buss M. and Daddona P.E. (1984). Immunohistochemistry of adenosine deaminase: Implications for adenosine neurotransmission. Science 224, 166-168.</Citation><ArticleIdList><ArticleId IdType="pubmed">6142530</ArticleId></ArticleIdList></Reference><Reference><Citation>Naumann M., Pal A., Goswami A., Lojewski X., Japtok J., Vehlow A., Naujock M., G&#xfc;nther R., Jin M., Stanslowsky N., Reinhardt P., Sterneckert J., Frickenhaus M., Pan-Montojo F., Storkebaum E., Poser I., Freischmidt A., Weishaupt J.H., Holzmann K., Troost D., Ludolph A.C., Boeckers T.M., Liebau S., Petri S., Cordes N., Hyman A.A., Wegner F., Grill S.W., Weis J., Storch A. and Hermann A. (2018). Impaired DNA damage response signaling by FUS-NLS mutations leads to neurodegeneration and FUS aggregate formation. Nat. Commun. 9, 335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5780468</ArticleId><ArticleId IdType="pubmed">29362359</ArticleId></ArticleIdList></Reference><Reference><Citation>Navon Elkan P., Pierce S.B., Segel R., Walsh T., Barash J., Padeh S., Zlotogorski A., Berkun Y., Press J.J., Mukamel M., Voth I., Hashkes P.J., Harel L., Hoffer V., Ling E., Yalcinkaya F., Kasapcopur O., Lee M.K., Klevit R.E., Renbaum P., Weinberg-Shukron A., Sener E.F., Schormair B., Zeligson S., Marek-Yagel D., Strom T.M., Shohat M., Singer A., Rubinow A., Pras E., Winkelmann J., Tekin M., Anikster Y., King M-C. and Levy-Lahad E. (2014). Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N. Engl. J. Med. 370, 921-931.</Citation><ArticleIdList><ArticleId IdType="pubmed">24552285</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen S., Meletis K., Fu D., Jhaveri S. and Jaenisch R. (2007). Ablation of de novo DNA methyltransferase Dnmt3a in the nervous system leads to neuromuscular defects and shortened lifespan. Dev. Dyn. 236, 1663-1676.</Citation><ArticleIdList><ArticleId IdType="pubmed">17477386</ArticleId></ArticleIdList></Reference><Reference><Citation>Nihei Y., Mori K., Werner G., Arzberger T., Zhou Q., Khosravi B., Japtok J., Hermann A., Sommacal A., Weber M., German Consortium for Frontotemporal Lobar Degeneration, Bavarian Brain Banking Alliance, Kamp F., Nuscher B., Edbauer D. and Haass C. (2020). Poly-glycine-alanine exacerbates C9orf72 repeat expansionmediated DNA damage via sequestration of phosphorylated ATM and loss of nuclear hnRNPA3. Acta Neuropathol. 139, 99</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6942035</ArticleId><ArticleId IdType="pubmed">31642962</ArticleId></ArticleIdList></Reference><Reference><Citation>Niraula A., Thapa S., Kunwar S., Lamsal M., Baral N. and Maskey R. (2018). Adenosine deaminase activity in type 2 diabetes mellitus: Does it have any role? BMC Endocr. Disord. 18, 58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6102918</ArticleId><ArticleId IdType="pubmed">30126383</ArticleId></ArticleIdList></Reference><Reference><Citation>Nofech-Mozes Y., Blaser S.I., Kobayashi J., Grunebaum E. and Roifman C.M. (2007). Neurologic abnormalities in patients with adenosine deaminase deficiency. Pediatr. Neurol. 37, 218-221.</Citation><ArticleIdList><ArticleId IdType="pubmed">17765813</ArticleId></ArticleIdList></Reference><Reference><Citation>Novitskiy S.V., Ryzhov S., Zaynagetdinov R., Goldstein A.E., Huang Y., Tikhomirov O.Y., Blackburn M.R., Biaggioni I., Carbone D.P., Feoktistov I. and Dikov M.M. (2008). Adenosine receptors in regulation of dendritic cell differentiation and function. Blood 112, 1822-1831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2518889</ArticleId><ArticleId IdType="pubmed">18559975</ArticleId></ArticleIdList></Reference><Reference><Citation>Oates N. and Pamphlett R. (2006). An epigenetic analysis of SOD1 and VEGF in ALS. Amyotroph. Lateral Scler. 8, 83-86.</Citation><ArticleIdList><ArticleId IdType="pubmed">17453634</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh S-I., Baek S., Park J.S., Piao L., Oh K.W. and Kim S.H. (2015). Prognostic role of serum levels of uric acid in amyotrophic lateral sclerosis. J. Clin. Neurol. 11, 376-382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4596112</ArticleId><ArticleId IdType="pubmed">26424237</ArticleId></ArticleIdList></Reference><Reference><Citation>Ombrello A.K., Qin J., Hoffmann P.M., Kumar P., Stone D., Jones A., Romeo T., Barham B., Pinto-Patarroyo G., Toro C., Soldatos A., Zhou Q., Deuitch N., Aksentijevich I., Sheldon S.L., Kelly S., Man A., Barron K., Hershfield M.S., Flegel W.A. and Kastner D.L. (2019). Treatment strategies for deficiency of adenosine deaminase 2. N. Engl. J. Med. 380, 1582-1584.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7372950</ArticleId><ArticleId IdType="pubmed">30995379</ArticleId></ArticleIdList></Reference><Reference><Citation>Pacheco R., Martinez-Navio J.M., Lejeune M., Climent N., Oliva H., Gatell J.M., Gallart T., Mallol J., Lluis C. and Franco R. (2005). CD26, adenosine deaminase and adenosine receptors mediate costimulatory signals in the immunological synapse. Proc. Natl. Acad. Sci. USA 102, 9583-9588.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1172240</ArticleId><ArticleId IdType="pubmed">15983379</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S., Zhang M., Z&#xe1;rate A.Q., Jaffa M., Yu H., Cudkowicz M.E. and Wills A.M. (2012). Uric acid levels predict survival in men with amyotrophic lateral sclerosis. J. Neurol. 259, 1923-1928.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4441749</ArticleId><ArticleId IdType="pubmed">22323210</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedley A.M. and Benkovic S.J. (2017). A new view into the regulation of purine metabolism: The purinosome. Trends. Biochem. Sci. 42, 141- 154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5272809</ArticleId><ArticleId IdType="pubmed">28029518</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellerin L. and Magistretti PJ. (1994). Glutamate uptake into astrocytes stimulates aerobic glycolysis: A mechanism coupling neuronal activity to glucose utilization. Proc. Natl. Acad. Sci. USA 91, 10625- 10629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC45074</ArticleId><ArticleId IdType="pubmed">7938003</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen M.B., Tranebjaerg L., Tommerup N., Nygaard P. and Edwards H. (1987). New assignment of the adenosine deaminase gene locus to chromosome 20q13&#xb7;11 by study of a patient with interstitial deletion 20q. J. Med. Genet. 24, 93-96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1049896</ArticleId><ArticleId IdType="pubmed">3560174</ArticleId></ArticleIdList></Reference><Reference><Citation>Polci R., Peng A., Chen P-L., Riley D.J. and Chen Y. (2004). NIMArelated protein kinase 1 is involved early in the ionizing radiationinduced DNA damage response. Cancer Res. 64, 8800-8803.</Citation><ArticleIdList><ArticleId IdType="pubmed">15604234</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozniak C.D., Radinovic S., Yang A., McKeon F., Kaplan D.R. and Miller F.D. (2000). An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. Science 289, 304-306.</Citation><ArticleIdList><ArticleId IdType="pubmed">10894779</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratech H., Thorbecke G.J., Meredith G. and Hirschhorn R. (1981). Comparison and possible homology of isozymes of adenosine deaminase in aves and humans. Enzyme 26, 74-84.</Citation><ArticleIdList><ArticleId IdType="pubmed">7238474</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren X. and Chen J.F. (2020). Caffeine and Parkinson&#x2019;s disease: multiple benefits and emerging mechanisms. Front. Neurosci. 14, 602697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7773776</ArticleId><ArticleId IdType="pubmed">33390888</ArticleId></ArticleIdList></Reference><Reference><Citation>Riazi M.A., Brinkman-Mills P., Nguyen T., Pan H., Phan S., Ying F., Roe B.A., Tochigi J., Shimizu Y., Minoshima S., Shimizu N., Buchwald M. and McDermid H.E. (2000). The human homolog of insect-derived growth factor, CECR1, is a candidate gene for features of cat eye syndrome. Genomics 64, 277-285.</Citation><ArticleIdList><ArticleId IdType="pubmed">10756095</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogakou E.P., Boon C., Redon C. and Bonner W.M. (1999). Megabase chromatin domains involved in DNA double-strand breaks in vivo. J. Cell Biol. 146, 905-916.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2169482</ArticleId><ArticleId IdType="pubmed">10477747</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers M.H., Lwin R., Fairbanks L., Gerritsen B. and Gaspar H.B. (2001). Cognitive and behavioral abnormalities in adenosine deaminase deficient severe combined immunodeficiency. J. Pediatr. 139, 44-50.</Citation><ArticleIdList><ArticleId IdType="pubmed">11445793</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., O&#x2019;Regan J.P., Deng H.X., Rahmani Z., Krizus A., McKenna-Yasek D., Cayabyab A., Gaston S.M., Berger R., Tanzi R.E., Halperin J.J., Herzfeldt B., Van den Bergh R., Hung W-Y., Bird T., Deng G., Mulder D.W., Smyth C., Laing N.G., Soriano E., Pericak&#x2013;Vance M.A., Haines J., Rouleau G.A., Gusella J.S., Horvitz H.R. and Brown Jr R.H. (1993). Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362, 59-62.</Citation><ArticleIdList><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudolphi K.A., Schubert P., Parkinson F.E. and Fredholm B.B. (1992). Adenosine and brain ischemia. Cerebrovasc. Brain Metab. Rev. 4, 346-369.</Citation><ArticleIdList><ArticleId IdType="pubmed">1486019</ArticleId></ArticleIdList></Reference><Reference><Citation>Rusconi M., Gerardi F., Santus W., Lizio A., Sansone V.A., Lunetta C., Zanoni I. and Granucci F. (2017). Inflammatory role of dendritic cells in amyotrophic lateral sclerosis revealed by an analysis of patients&#x2019; peripheral blood. Sci. Rep. 7, 7835.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5552769</ArticleId><ArticleId IdType="pubmed">28798369</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell K.L., Downie J.M., Gibson S.B., Tsetsou S., Keefe M.D., Duran J.A., Figueroa K.P., Bromberg M.B., Murtaugh L.C., Bonkowsky J.L., Pulst S.M. and Jorde L.B. (2021). Pathogenic effect of TP73 gene variants in people with amyotrophic lateral sclerosis. Neurology 97, e225-235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8302149</ArticleId><ArticleId IdType="pubmed">34135078</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutkiewicz J. and G&#xf3;rski J. (1990). On the role of insulin in regulation of adenosine deaminase activity in rat tissues. FEBS Lett. 271, 79-80.</Citation><ArticleIdList><ArticleId IdType="pubmed">2146155</ArticleId></ArticleIdList></Reference><Reference><Citation>Santisteban I., Arredondo-Vega F.X., Kelly S., Mary A., Fischer A., Hummell D.S., Lawton A., Sorensen R.U., Stiehm E.R. and Uribe L. (1993). Novel splicing, missense and deletion mutations in seven adenosine deaminase-deficient patients with late/delayed onset of combined immunodeficiency disease. contribution of genotype to phenotype. J. Clin. Invest. 92, 2291-2302</Citation><ArticleIdList><ArticleId IdType="pmc">PMC288410</ArticleId><ArticleId IdType="pubmed">8227344</ArticleId></ArticleIdList></Reference><Reference><Citation>Santisteban I., Arredondo-Vega F.X., Kelly S., Loubser M., Meydan N., Roifman C., Howell P.L., Bowen T., Weinberg K.I. and Schroeder M.L. (1995). Three new adenosine deaminase mutations that define a splicing enhancer and cause severe and partial phenotypes: Implications for evolution of a CpG hotspot and expression of a transduced ADA CDNA. Hum. Mol. Genet. 4, 2081-2087.</Citation><ArticleIdList><ArticleId IdType="pubmed">8589684</ArticleId></ArticleIdList></Reference><Reference><Citation>Sau, D., De Biasi S., Vitellaro-Zuccarello L., Riso P., Guarnieri S., Porrini M., Simeoni S., Crippa V., Onesto E., Palazzolo I., Rusmini P., Bolzoni E., Bendotti C. and Poletti A. (2007). Mutation of SOD1 in ALS: A gain of a loss of function. Hum. Mol. Genet. 16, 1604- 1618.</Citation><ArticleIdList><ArticleId IdType="pubmed">17504823</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauer A.V., Hernandez R.J., Fumagalli F., Bianchi V., Poliani P.L., Dallatomasina C., Riboni E., Politi L.S., Tabucchi A., Carlucci F., Casiraghi M., Carriglio N., Cominelli M., Forcellini C.A., Barzaghi F., Ferrua F., Minicucci F., Medaglini S., Leocani L., la Marca G., Notarangelo L.D., Azzari C., Comi G., Baldoli C., Canale S., Sessa M., D&#x2019;Adamo P. and Aiuti A. (2017). Alterations in the brain adenosine metabolism cause behavioral and neurological impairment in ADA-deficient mice and patients. Sci. Rep. 7, 1-13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5225479</ArticleId><ArticleId IdType="pubmed">28074903</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura C., Ciruela F., Casad&#xf3; V., Canela E.I., Mallol J., Lluis C. and Franco R. (1996). Adenosine deaminase interacts with A1 adenosine receptors in pig brain cortical membranes. J. Neurochem. 66, 1675-1682.</Citation><ArticleIdList><ArticleId IdType="pubmed">8627325</ArticleId></ArticleIdList></Reference><Reference><Citation>Sbis&#xe0; E., Mastropasqua G., Lefkimmiatis K., Caratozzolo M.F., D&#x2019;Erchia A.M. and Tullo A. (2006). Connecting p63 to cellular proliferation: The example of the adenosine deaminase target gene. Cell Cycle 5, 205-212.</Citation><ArticleIdList><ArticleId IdType="pubmed">16410722</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrader WP., Pollara B. and Meuwissen HJ. (1978). Characterization of the residual adenosine deaminating activity in the spleen of a patient with combined immunodeficiency disease and adenosine deaminase deficiency. Proc. Natl. Acad. Sci. USA 75, 446-450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC411266</ArticleId><ArticleId IdType="pubmed">24216</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott O., Kim V.H., Reid B., Pham-Huy A., Atkinson A.R., Aiuti A. and Grunebaum E. (2017). Long-term outcome of adenosine deaminase-deficient patients-a single-center experience. J. Clin. Immunol. 37, 582-591.</Citation><ArticleIdList><ArticleId IdType="pubmed">28748310</ArticleId></ArticleIdList></Reference><Reference><Citation>Sebasti&#xe3;o A.M., de Mendonca A., Moreira T. and Ribeiro J.A. (2001). Activation of synaptic NMDA receptors by action potentialdependent release of transmitter during hypoxia impairs recovery of synaptic transmission on reoxygenation. J. Neurosci. 21, 8564-8571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762820</ArticleId><ArticleId IdType="pubmed">11606644</ArticleId></ArticleIdList></Reference><Reference><Citation>Sebasti&#xe3;o A.M., Rei N. and Ribeiro J.A. (2018). Amyotrophic lateral sclerosis (ALS) and adenosine receptors. Front. Pharmacol. 9, 267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5911503</ArticleId><ArticleId IdType="pubmed">29713276</ArticleId></ArticleIdList></Reference><Reference><Citation>Shekhar S. and Dey S. (2019). Induction of p73, &#x394;133p53, &#x394;160p53, PAKT lead to neuroprotection via DNA repair by 5-LOX inhibition. Mol. Biol. Rep. 47, 269-274.</Citation><ArticleIdList><ArticleId IdType="pubmed">31659693</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheth K.J., Swick H.M. and Haworth N. (1986). Neurological involvement in hemolytic-uremic syndrome. Ann. Neurol. 19, 90-93.</Citation><ArticleIdList><ArticleId IdType="pubmed">3947042</ArticleId></ArticleIdList></Reference><Reference><Citation>Sims-Robinson C., Kim B., Rosko A. and Feldman E.L. (2010). How does diabetes accelerate Alzheimer disease pathology?. Nat. Rev. Neurol. 6, 551-559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3199576</ArticleId><ArticleId IdType="pubmed">20842183</ArticleId></ArticleIdList></Reference><Reference><Citation>Sitkovsky M.V. and Ohta A. (2005). The &#x2018;danger&#x2019; sensors that STOP the immune response: The A2 adenosine receptors?. Trends Immunol. 26, 299-304.</Citation><ArticleIdList><ArticleId IdType="pubmed">15922945</ArticleId></ArticleIdList></Reference><Reference><Citation>Skaldin M., Tuittila M. Zavialov A.V. and Zavialov A.V. (2018). Secreted bacterial adenosine deaminase is an evolutionary precursor of adenosine deaminase growth factor. Mol. Biol. Evol. 35, 2851-2861</Citation><ArticleIdList><ArticleId IdType="pubmed">30325443</ArticleId></ArticleIdList></Reference><Reference><Citation>Springer J.M., Gierer S.A., Jiang H., Kleiner D., Deuitch N., Ombrello A.K., Grayson P.C. and Aksentijevich I. (2018). Deficiency of adenosine deaminase 2 in adult siblings: Many years of a misdiagnosed disease with severe consequences. Front. Immunol. 9, 1361.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6010516</ArticleId><ArticleId IdType="pubmed">29963054</ArticleId></ArticleIdList></Reference><Reference><Citation>Staknis D. and Reed R. (1994). SR proteins promote the first specific recognition of pre-mRNA and are present together with the U1 small nuclear ribonucleoprotein particle in a general splicing enhancer complex. Mol. Cell. Biol. 14, 7670-7682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC359303</ArticleId><ArticleId IdType="pubmed">7935481</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoccoro A., Mosca L., Carnicelli V., Cavallari U., Lunetta C., Marocchi A., Migliore L. and Copped&#xe8; F. (2018). Mitochondrial DNA copy number and D-loop region methylation in carriers of amyotrophic lateral sclerosis gene mutations. Epigenomics 10, 1431-1443.</Citation><ArticleIdList><ArticleId IdType="pubmed">30088417</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoccoro A., Smith AR., Mosca L., Marocchi A., Gerardi F., Lunetta C., Cereda C., Gagliardi S., Lunnon K., Migliore L. and Copped&#xe8; F. (2020). Reduced mitochondrial D-loop methylation levels in sporadic amyotrophic lateral sclerosis. Clin. Epigenetics 12, 137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7488473</ArticleId><ArticleId IdType="pubmed">32917270</ArticleId></ArticleIdList></Reference><Reference><Citation>Stubbs G., Litt M., Lis E., Jackson R., Voth W., Lindberg A. and Litt R. (1982). Adenosine deaminase activity decreased in autism. J. Am. Acad. Child Psychiatry 21, 71-74.</Citation><ArticleIdList><ArticleId IdType="pubmed">7096833</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki H. and Matsuoka M. (2021). Proline-arginine poly-dipeptide encoded by the C9orf72 repeat expansion inhibits adenosine deaminase acting on RNA. J. Neurochem. 158, 753-765.</Citation><ArticleIdList><ArticleId IdType="pubmed">34081786</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka C., Hara T., Suzaki I., Maegaki Y. and Takeshita K. (1996). Sensorineural deafness in siblings with adenosine deaminase deficiency. Brain Dev. 18, 304-306.</Citation><ArticleIdList><ArticleId IdType="pubmed">8879650</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka K., Watakabe A. and Shimura Y. (1994). Polypurine sequences within a downstream exon function as a splicing enhancer. Mol. Cell. Biol. 14, 1347-1354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC358489</ArticleId><ArticleId IdType="pubmed">8289812</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian M. and Maniatis T. (1993). A splicing enhancer complex controls alternative splicing of doublesex pre-mRNA. Cell 74, 105-114.</Citation><ArticleIdList><ArticleId IdType="pubmed">8334698</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian M. and Maniatis T. (1994). A splicing enhancer exhibits both constitutive and regulated activities. Genes Dev. 8, 1703-1712.</Citation><ArticleIdList><ArticleId IdType="pubmed">7958850</ArticleId></ArticleIdList></Reference><Reference><Citation>Tissir F., Ravni A., Achouri Y., Riethmacher D., Meyer G. and Goffinet A.M. (2009). DeltaNp73 regulates neuronal survival in vivo. Proc. Natl. Acad. Sci. USA 106, 16871-16876.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2757832</ArticleId><ArticleId IdType="pubmed">19805388</ArticleId></ArticleIdList></Reference><Reference><Citation>Titman P., Pink E., Skucek E., O&#x2019;Hanlon K., Cole T.J., Gaspar J., XuBayford J., Jones A., Thrasher A.J., Davies E.G., Veys P.A. and Gaspar H.B. (2008). Cognitive and behavioral abnormalities in children after hematopoietic stem cell transplantation for severe congenital immunodeficiencies. Blood 112, 3907-3913.</Citation><ArticleIdList><ArticleId IdType="pubmed">18645040</ArticleId></ArticleIdList></Reference><Reference><Citation>Tremolizzo L., Messina P., Conti E., Sala G., Cecchi M., Airoldi L., Pastorelli R., Pupillo E., Di Poggio M.B., Filosto M., Lunetta C., Agliardi C., Guerini F., Mandrioli J., Calvo A., Beghi E., Ferrarese C. and EURALS Consortium. (2014). Whole-blood global DNA methylation is increased in amyotrophic lateral sclerosis independently of age of onset. Amyotroph. Lateral Scler. Frontotemporal Degener. 15, 98-105.</Citation><ArticleIdList><ArticleId IdType="pubmed">24224837</ArticleId></ArticleIdList></Reference><Reference><Citation>Tritsch G.L. and Niswander P.W. (1981). Adenosine deaminase activity and superoxide formation during phagocytosis and membrane perturbation of macrophages. Immunol. Commun. 10, 1-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">6268529</ArticleId></ArticleIdList></Reference><Reference><Citation>Trussell L.O. and Jackson M.B. (1985). Adenosine-activated potassium conductance in cultured striatal neurons. Proc. Natl. Acad. Sci. USA 82, 4857-4861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC391004</ArticleId><ArticleId IdType="pubmed">2991897</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai C.P., Lee J.K. and Lee C.T. (2019). Type II diabetes mellitus and the incidence of amyotrophic lateral sclerosis. J. Neurol. 266, 2233- 2243.</Citation><ArticleIdList><ArticleId IdType="pubmed">31152300</ArticleId></ArticleIdList></Reference><Reference><Citation>Tullo A., Mastropasqua G., Bourdon J.C., Centonze P., Gostissa M., Costanzo A., Levrero M., Del Sal G., Saccone G. and Sbis&#xe0; E. (2003). Adenosine deaminase, a key enzyme in DNA precursors control, is a new p73 target. Oncogene 22, 8738-8748.</Citation><ArticleIdList><ArticleId IdType="pubmed">14647469</ArticleId></ArticleIdList></Reference><Reference><Citation>Ungerer J.P., Oosthuizen H.M., Bissbort S.H. and Vermaak W.J. (1992). Serum adenosine deaminase: Isoenzymes and diagnostic application. Clin. Chem. 38, 1322-1326.</Citation><ArticleIdList><ArticleId IdType="pubmed">1623598</ArticleId></ArticleIdList></Reference><Reference><Citation>Valentine W.N., Paglia D.E., Tartaglia A.P. and Gilsanz F. (1977). Hereditary hemolytic anemia with increased red cell adenosine deaminase (45- to 70-fold) and decreased adenosine triphosphate. Science 195, 783-785.</Citation><ArticleIdList><ArticleId IdType="pubmed">836588</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Der Weyden M.B. and Kelley W.N. (1976). Human adenosine deaminase. distribution and properties. J. Biol. Chem. 251, 5448- 5456.</Citation><ArticleIdList><ArticleId IdType="pubmed">9388</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Es M.A., Hardiman O., Chio A., Al-Chalabi A., Pasterkamp R.J., Veldink J.H. and van den Berg L.H. (2017). Amyotrophic lateral sclerosis. Lancet 39, 2084-2098.</Citation><ArticleIdList><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Linden A. and Eltzschig H.K. (2007). Role of pulmonary adenosine during hypoxia: Extracellular generation, signaling and metabolism by surface adenosine deaminase/CD26. Expert Opin. Biol. Ther. 7, 1437-1447.</Citation><ArticleIdList><ArticleId IdType="pubmed">17727332</ArticleId></ArticleIdList></Reference><Reference><Citation>Vardarajan B., Vergote D., Tissir F., Logue M., Yang J., Daude N., Ando K., Rogaeva E., Lee J., Cheng R., Brion J-P., Ghani M., Shi B., Baldwin C.T., Kar S., Mayeux R., Fraser P., Goffinet A.M., St George-Hyslop P., Farrer LA. and Westaway D. (2013). Role of p73 in Alzheimer disease: Lack of association in mouse models or in human cohorts. Mol. Neurodegener. 8, 1-14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3424147</ArticleId><ArticleId IdType="pubmed">22651796</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker C., Herranz-Martin S., Karyka E., Liao C., Lewis K., Elsayed W, Lukashchuk V., Chiang S-C., Ray S., Mulcahy P.J., Jurga M., Tsagakis I., Iannitti T., Chandran J., Coldicott I., De Vos K.J., Hassan M.K., Higginbottom A., Shaw P.J., Hautbergue G.M., Azzouz M. and El-Khamisy S.F. (2017). C9orf72 expansion disrupts ATM-mMediated chromosomal break repair. Nat. Neurosci. 20, 1225-1235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5578434</ArticleId><ArticleId IdType="pubmed">28714954</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X.D., Zhu W., Shan D., Wang S.Y., Yin X., Yang Y.Q., Wang T.H., Zhang C-T., Wang Y., Liang W-W., Zhang J., Jiang H-Z., Dong G-T., Jiang H-Q., Qi Y. and Feng H-L. (2019). Spy1, a unique cell cycle regulator, alters viability in ALS motor neurons and cell lines in response to mutant SOD1-induced DNA damage. DNA Repair. 74, 51-62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5578434</ArticleId><ArticleId IdType="pubmed">28714954</ArticleId></ArticleIdList></Reference><Reference><Citation>Warita H., Hayashi T., Murakami T., Manabe Y. and Abe K. (2001). Oxidative damage to mitochondrial DNA in spinal motoneurons of transgenic ALS mice. Mol. Brain Res. 89, 147-152.</Citation><ArticleIdList><ArticleId IdType="pubmed">11311985</ArticleId></ArticleIdList></Reference><Reference><Citation>Watakabe A., Tanaka K. and Shimura Y. (1993). The role of exon sequences in splice site selection. Genes. Dev. 7, 407-418</Citation><ArticleIdList><ArticleId IdType="pubmed">8449402</ArticleId></ArticleIdList></Reference><Reference><Citation>Weihofen W.A., Liu J., Reutter W., Saenger W. and Fan H. (2004). Crystal Structure of CD26/dipeptidyl-peptidase IV in complex with adenosine deaminase reveals a highly amphiphilic interface. J. Biol. Chem. 279, 43330-43335.</Citation><ArticleIdList><ArticleId IdType="pubmed">15213224</ArticleId></ArticleIdList></Reference><Reference><Citation>Wetzel M.K., Naska S., Lalibert&#xe9; C.L., Rymar V.V., Fujitani M., Biernaskie J.A., Cole C.J., Lerch J.P., Spring S., Wang S-H., Frankland P.W., Henkelman R.M., Josselyn S.A., Sadikot A.F., Miller F.D. and Kaplan D.R. (2008). p73 regulates neurodegeneration and phospho-tau accumulation during aging and Alzheimer&#x2019;s disease. Neuron 59, 708-721.</Citation><ArticleIdList><ArticleId IdType="pubmed">18786355</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilhelm M.T., Rufini A., Wetzel M.K., Tsuchihara K., Inoue S., Tomasini R., Itie-Youten A., Wakeham A., Arsenian-Henriksson M., Melino G., Kaplan D.R., Miller F.D. and Mak T.W. (2010). Isoform-specific p73 knockout mice reveal a novel role for &#x394;Np73 in the DNA damage response pathway. Genes. Dev. 24, 549-560.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2841333</ArticleId><ArticleId IdType="pubmed">20194434</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson D.K., Rudolph F.B. and Quiocho F.A. (1991). Atomic structure of adenosine deaminase complexed with a transition-state analog: understanding catalysis and immunodeficiency mutations. Science 252, 1278-1284.</Citation><ArticleIdList><ArticleId IdType="pubmed">1925539</ArticleId></ArticleIdList></Reference><Reference><Citation>Winn H.R., Rubio R. and Berne RM. (1981). Brain adenosine concentration during hypoxia in rats. Am. J. Physiol. 241, 235-242.</Citation><ArticleIdList><ArticleId IdType="pubmed">6791511</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong M., Gertz B., Chestnut B.A. and Martin L.J. (2013). Mitochondrial DNMT3A and DNA methylation in skeletal muscle and CNS of transgenic mouse models of ALS. Front. Cell. Neurosci. 7, 279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3872319</ArticleId><ArticleId IdType="pubmed">24399935</ArticleId></ArticleIdList></Reference><Reference><Citation>Xi Z., Zinman L., Moreno D., Schymick J., Liang Y., Sato C., Zheng Y., Ghani M., Dib S., Keith J., Robertson J. and Rogaeva E. (2013). Hypermethylation of the CpG island near the G4C2 repeat in ALS with a C9orf72 expansion. Am. J. Hum. Genet. 92, 981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3675239</ArticleId><ArticleId IdType="pubmed">23731538</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie W., Duan R. and Safe S. (2001). Activation of adenosine deaminase in MCF-7 cells through IGF-estrogen receptor alpha crosstalk. J. Mol. Endocrinol. 26, 217-228.</Citation><ArticleIdList><ArticleId IdType="pubmed">11357058</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie W., Duan R. and Safe S. (1999). Estrogen induces adenosine deaminase gene expression in MCF-7 human breast cancer cells: role of estrogen receptor-Sp1 interactions. Endocrinology 140, 219-227.</Citation><ArticleIdList><ArticleId IdType="pubmed">9886828</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu X., Su Y., Zou Z., Zhou Y. and Yan J. (2021). Correlation between C9ORF72 mutation and neurodegenerative diseases: A comprehensive review of the literature. Int. J. Med. Sci. 18, 378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7757155</ArticleId><ArticleId IdType="pubmed">33390807</ArticleId></ArticleIdList></Reference><Reference><Citation>Yagawa K. and Okamura J. (1981). Role of adenosine deaminase in activation of macrophages. Infect. Immun. 32, 394-397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC350633</ArticleId><ArticleId IdType="pubmed">6260686</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang A., Kaghad M., Wang Y., Gillett E., Fleming M.D., D&#xf6;tsch V., Andrews N.C., Caput D. and McKeon F. (1998). p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, deathinducing and dominant-negative activities. Mol. Cell 2, 305-316.</Citation><ArticleIdList><ArticleId IdType="pubmed">9774969</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang A., Walker N., Bronson R., Kaghad M., Oosterwegel M., Bonnin J., Vagner C., Bonnet H., Dikkes P., Sharpe A., McKeon F. and Caput D. (2000). p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 404, 99- 103.</Citation><ArticleIdList><ArticleId IdType="pubmed">10716451</ArticleId></ArticleIdList></Reference><Reference><Citation>Zavialov A.V. and Engstr&#xf6;m A. (2005). Human ADA2 belongs to a new family of growth factors with adenosine deaminase activity. Biochem. J. 391, 51-57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1237138</ArticleId><ArticleId IdType="pubmed">15926889</ArticleId></ArticleIdList></Reference><Reference><Citation>Zavialov A.V., Yu X., Spillmann D., Lauvau G. and Zavialov A.V. (2010a). Structural basis for the growth factor activity of human adenosine deaminase ADA2. J. Biol. Chem. 285, 12367-12377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2852975</ArticleId><ArticleId IdType="pubmed">20147294</ArticleId></ArticleIdList></Reference><Reference><Citation>Zavialov A.V., Gracia E., Glaichenhaus N., Franco R., Zavialov A.V. and Lauvau G. (2010b). Human adenosine deaminase 2 induces differentiation of monocytes into macrophages and stimulates proliferation of T helper cells and macrophages. J. Leukoc. Biol. 88, 279-290.</Citation><ArticleIdList><ArticleId IdType="pubmed">20453107</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng P., Wang T., Zheng J. and Zhou X. (2019). Causal association of type 2 diabetes with amyotrophic lateral sclerosis: New evidence from mendelian randomization using GWAS summary statistics. BMC Med. 17, 1-13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6892209</ArticleId><ArticleId IdType="pubmed">31796040</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C., Yang Y., Liang W., Wang T., Wang S., Wang X., Wang Y., Jiang H. and Feng H. (2019). Neuroprotection by urate on the mutant HSOD1-related cellular and drosophila models of amyotrophic lateral sclerosis: Implication for GSH synthesis via activating Akt/GSK3&#x3b2;/Nrf2/GCLC pathways. Brain Res. Bull. 146, 287-301.</Citation><ArticleIdList><ArticleId IdType="pubmed">30690059</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao H., Chiaro C.R., Zhang L., Smith P.B., Chan C.Y., Pedley A.M., Pugh R.J., French J.B., Patterson A.D. and Benkovic SJ. (2015). Quantitative analysis of purine nucleotides indicates that purinosomes increase de novo purine biosynthesis. J. Biol. Chem. 290, 6705-6713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4358094</ArticleId><ArticleId IdType="pubmed">25605736</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W., Beers D.R., Hooten K.G., Sieglaff D.H., Zhang A., KalyanaSundaram S., Traini C.M., Halsey W.S., Hughes A.M., Sathe G.M., Livi G.P., Fan G-H. and Appel S.H. (2017). Characterization of gene expression phenotype in amyotrophic lateral sclerosis monocytes. JAMA Neurol. 74, 677-685.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822209</ArticleId><ArticleId IdType="pubmed">28437540</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Q., Yang D., Ombrello A-K., Zavialov A.V., Toro C., Zavialov A.V., Stone D.L., Chae J.J., Rosenzweig S.D., Bishop K., Barron K-S., Kuehn H.S., Hoffmann P., Negro A., Tsai W.L., Cowen E.W., Pei W., Milner J.D., Silvin C., Heller T., Chin D.T., Patronas N.J., Barber J.S., Lee C.C., Wood G.M., Ling A., Kelly S.J., Kleiner D.E., Mullikin J.C., Ganson N.J., Kong H.H., Hambleton S., Candotti F., Quezado M.M., Calvo K.R., Alao H., Barham B.K., Jones A., Meschia J.F., Worrall B.B., Kasner S.E., Rich S.S., Goldbach-Mansky R., Abinun M., Chalom E., Gotte A.C., Punaro M., Pascual V., Verbsky J.W., Torgerson T.R., Singer N.G., Gershon T.R., Ozen S., Karadag O., Fleisher T.A., Remmers E.F., Burgess S.M., Moir S.L., Gadina M., Sood R., Hershfield M.S., Boehm M., Kastner D.L. and Aksentijevich I. (2014). Early-onset stroke and vasculopathy associated with mutations in ADA2. N. Engl. J. Med. 370, 911-920.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4193683</ArticleId><ArticleId IdType="pubmed">24552284</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmermann F.F., Gaspary K.V., Siebel A.M., Leite C.E., Kist L.W., Bogo M.R. and Bonan C.D. (2016). Analysis of extracellular nucleotide metabolism in adult zebrafish after embryological exposure to valproic acid. Mol. Neurobiol. 54, 3542-3553.</Citation><ArticleIdList><ArticleId IdType="pubmed">27189619</ArticleId></ArticleIdList></Reference><Reference><Citation>Zondler L., M&#xfc;ller K., Khalaji S., Bliederh&#xe4;user C., Ruf W.P., Grozdanov V., Thiemann M., Fundel-Clemes K., Freischmidt A., Holzmann K., Strobel B., Weydt P., Witting A., Thal D.R., Helferich A.M., Hengerer B., Gottschalk K.E., Hill O., Kluge M., Ludolph A.C., Danzer K.M. and Weishaupt J.H. (2016). Peripheral monocytes are functionally altered and invade the CNS in ALS patients. Acta Neuropathol. 132, 391-411.</Citation><ArticleIdList><ArticleId IdType="pubmed">26910103</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>